Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study of CVN293 assessing safety, tolerability, and pharmacokinetics in healthy subjects

Next Previous
Trial Profile

A phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study of CVN293 assessing safety, tolerability, and pharmacokinetics in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CVN-293 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man

Most Recent Events

  • 08 Apr 2025 According to a Cerevance media release, data of this trial was presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego.
  • 27 Mar 2025 According to a Cerevance media release, data from this study to be presented at the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 in San Diego.
  • 11 Nov 2024 Results published in the Cerevance Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top